Lupin latest target of Teijin/Takeda's febuxostat defense
This article was originally published in Scrip
Executive Summary
India's Lupin has become the latest target to move into the legal sights of two Japanese firms over its plans to launch a generic version of the gout drug Uloric (febuxostat) in the US.